According to the National Heart, Lung and Blood Institute, the decline in cardiovascular disease related deaths are attributed to the advances made in medical technology, which have impacted diagnosis and treatment. As an expert in the cardiovascular market, Philips has formed relationships with several renowned cardiovascular centres to help develop medical technologies that more effectively identify and treat cardiovascular disease.
"Fast and accurate diagnosis and treatment of cardiovascular disease is critical to saving lives", stated Mark Goodwin, M.D., director of the Edward Heart Hospital cath lab and member of Midwest Heart Specialists. "Medical imaging technologies, like Philips StentBoost, are making this possible by helping me identify problems quickly and effectively and ensuring that patients receive the best possible care."
Another component of Philips success in the cardiovascular market are its impressive research partnerships which are designed to elicit technologies that enable cardiologists to detect diseases earlier, when they are less costly to treat, provide more effective and less invasive treatment options, and reduce recovery times.
Philips is working with several leading institutions to develop new technologies to identify heart and vascular conditions earlier and faster to help doctors more effectively plan treatment options. There are several CT research initiatives underway including the CATSCAN study comparing CT angiography and conventional diagnostic angiography.
Another multi-centre trial, called PERFECT, aims to advance CT's utilization in evaluating stroke victims, by furthering the perfusion advancements available in Philips new CT brain perfusion software package that recently received 510K clearance. A first-of-its-kind diagnostic tool, the perfusion software enables cardiologists to provide faster stroke detection and treatment plans by viewing detailed images of the blood flow to the brain.
Philips and its Cardiac Magnetic Resonance Network are developing a new three-dimensional coronary artery visualization technique for the Achieva CV MR system. The technique generates stunning photo-like images of the heart and coronary arteries from routine MR coronary artery scans. Thanks to the pooled expertise of Network members including the University of California San Francisco, St. Luke's Episcopal Hospital in Houston, and support from Philips experts, the technique has progressed from a concept to a budding clinical trial in just 12 months. The technique promises to improve cardiovascular care by enabling routine pre-cath lab MR screening of patients with suspected coronary artery disease, reducing patient exposure to ionizing radiation.
Philips successful collaboration with King's College London resulted in the development of groundbreaking new techniques for MR-guided cardiac catheterization of paediatric patients. MR-guided procedures proved safe and practical in a clinical setting, allowing better soft tissue visualization, providing more pertinent physiological information, and resulting in lower radiation exposure. Due to this research, MRI guidance could become the method of choice for diagnostic cardiac catheterization in patients with congenital heart disease, and an important tool in interventional cardiac catheterization and radiofrequency ablation.
Philips announced a recent collaboration agreement with EP MedSystems to integrate and develop technologies to advance treatment and diagnosis of cardiac rhythm disorders. By combining high-quality imaging at the lowest possible dose on the Philips Allura X-ray imaging system with the superior signal quality of the EP-WorkMate recording, stimulation, and mapping platform, EP MedSystems and Philips will offer electrophysiology solutions that will increase the overall effectiveness of patient procedures both now and in the future.
"Our relationship with Philips combines industry-leading technology and knowledge", stated Reinhard Schmidt, president and CEO of EP MedSystems. "We will work closely together in the near future to provide a complete EP lab solution for health care providers and continue to discover new technology that will advance the diagnosis and treatment of cardiac rhythm disorders."
In the past year, Philips has announced new strategic partnerships with global cardiovascular facilities including Clinique Pasteur, Toulouse, France; The Cleveland Clinic in Ohio; Edward Heart Hospital in Illinois; German Heart Center, Berlin, Germany; Leeds General Infirmary, Leeds, United Kingdom; Lenox Hill in Manhattan, New York; Massachusetts General in Boston; and Wisconsin Heart in Milwaukee. The objectives of these partnerships are to conduct research identifying new ways to diagnose and treat cardiovascular disease as well as provide state-of-the-art technologies to advance care.
"Cardiovascular disease is one of the most pervasive diseases in the world and it requires immediate action towards a solution; Philips believes that technology is an integral part of that solution", stated David Freeman, vice president, cardiology marketing, for Philips Medical Systems. "Building upon our collaborative approach and legacy of providing innovative and industry-leading imaging, diagnostic, IT and professional services, we are focused on developing technologies that speed diagnosis and treatment of cardiovascular disease."
The new Intera Achieva CV promises fast, easy routine cardiac MR incorporating non-invasive diagnostics and improved soft tissue definition. New PhysioTrak is a world first, providing continuous patient monitoring, fully integrated into Achieva's patient table. PhysioTrak provides for continuous patient care before, during and after MR procedures. The Coronary Artery Imaging package provides 2D and 3D full heart volume imaging in a simple procedure, without the use of a contrast agent. Achieva CV has been developed in close collaboration with Philips Cardiac Magnetic Resonance Network.
The JETStream Workspace for Cardiology is Philips' next generation nuclear cardiology software option. It combines all the imaging elements of a nuclear cardiology laboratory at a single location or throughout the department, including display, processing, review and reporting, and image archiving. This automates departmental work flow by allowing the user to define the steps of the procedure based on individual study requirements without compromising clinical accuracy.
The CVCT Private Practice package optimizes Philips Brilliance CVCT Rate Responsive system in a freestanding private clinic setting. The CVCT Private Practice package enables private practice cardiologists to streamline their work flow and conduct more efficient patient procedures, diagnosis and treatment.
Allura Xper FD20 is the latest addition to the Philips line of flat detector X-ray systems. The Allura Xper FD20 is the first cardiovascular system on the market to provide 2k x 2k imaging chain for four times the resolution of currently marketed systems. With its compact detector (12" x 16") and large coverage ability, it is designed to support all cardiac and vascular interventions. The system comprises a pivoting functionality for the detector, allowing landscape or portrait positioning over the patient. The Allura FD20 is designed with personalized X-ray technology, known as Xper (X-ray Personalized), to customize work flow by using preferred settings. In addition, the system offers the intuitive, Xper user interface and new information integration functionality.
Allura Xper FD10 is part of Philips' Allura series, the company's cardiovascular portfolio of interventional imaging systems. The Allura Xper FD10 offers unrivalled image quality with the real-time imaging algorithm Xres, enabling clinicians to see and work in the smallest vessels of the heart. Xper allows cardiologists to customize their work flow in the cath lab by using preferred settings.
Haemosphere, Philips' haemodynamic monitoring system is designed to promote efficient work flow within the cath lab and beyond, while providing the scalability to fulfill the needs of a multi-modality, multi-site heart care facility. A fully customizable monitoring, analysis and reporting system, it is based on dependable, proven technology that includes user-friendly functionality and compatibility with the Philips cardiovascular portfolio. Haemosphere is also integrated with Xcelera Cath Lab Management to promote efficient work flow in the cath lab by providing fully customizable monitoring, analysis and reporting.
Philips' Cardiac 3D Quantification is its low-cost, cardiac 3D viewer and quantification ultrasound software available for everyday use by clinicians. The latest addition to Philips QLAB quantification software, it provides easy access to full-fidelity Live 3D (4D) data sets for cropping, cutting and performing measurements on a standard PC and allows the mainstream clinician or sonographer to perform the image acquisition first and do the analysis later; potentially reducing scan time and helping users keep up with patient volume.
Philips' 7500 Performance 2005 upgrade with Live 3D Echo technology features Philips Live xPlane imaging for stress echo and some important 3D networking/connectivity updates to expand the availability of Live 3D images. Clinicians can acquire the multiple images necessary for a stress echo exam closer to peak stress allowing for more sensitive detection of wall motion abnormalities.
The Xcelera Cardiology Information Solution includes the optional Xcelera 3D Echo Viewing Module including functionality of the Philips 3DQ Plug-in, that, unlike current offerings, enables clinicians to view, crop, cut, perform measurements and archive 3D ultrasound data sets. In addition, Xcelera features paediatric z-scoring and measurement trending, which are displayed as graphs in the echocardiographer's report.
Philips products and technologies were displayed at the American College of Cardiology (ACC) Annual Scientific Sessions. Philips' booth also offered two virtual patient technology demonstrations: Gerard Donovan and Rita Williams, who are being treated for chest pain and arrhythmia respectively. Booth visitors were able to examine Gerard and Rita's case scenarios and follow each patient's treatment path on a single, fully integrated information system.